Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of play in a young cochlear implant user.
Nishioka N, Baba A, Yamaguchi S, Kawano M, Fujiki N, Naito Y, Honjo I. Nishioka N, et al. Adv Otorhinolaryngol. 2000;57:284-7. doi: 10.1159/000059129. Adv Otorhinolaryngol. 2000. PMID: 11892170 No abstract available.
Usefulness of a dedicated laser-cut metal stent with an anchoring hook and thin delivery system for endoscopic ultrasound-guided hepaticogastrostomy in malignant biliary obstruction: a prospective multicenter trial (with video).
Itonaga M, Ogura T, Isayama H, Takenaka M, Hijioka S, Ishiwatari H, Ashida R, Okuda A, Fujisawa T, Minaga K, Takeshita K, Yamashita Y, Nishioka N, Ishii S, Omoto S, Ohtsuka T, Sofue K, Yasuda I, Shimokawa T, Kitano M. Itonaga M, et al. Among authors: nishioka n. Gastrointest Endosc. 2024 Nov 7:S0016-5107(24)03686-1. doi: 10.1016/j.gie.2024.11.005. Online ahead of print. Gastrointest Endosc. 2024. PMID: 39521097
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study.
Nishioka N, Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K. Nishioka N, et al. Cancer Res Treat. 2024 Oct 25. doi: 10.4143/crt.2024.748. Online ahead of print. Cancer Res Treat. 2024. PMID: 39482992 Free article.
Technical feasibility of EUS-guided liver abscess drainage for the right hepatic lobe using a novel metal stent as first-line treatment (with video).
Ogura T, Ueno S, Okuda A, Nishioka N, Sakamoto J, Yamada M, Yamamura M, Uba Y, Tomita M, Hattori N, Nakamura J, Bessho K, Nishikawa H. Ogura T, et al. Among authors: nishioka n. Gastrointest Endosc. 2024 Sep 12:S0016-5107(24)03494-1. doi: 10.1016/j.gie.2024.09.013. Online ahead of print. Gastrointest Endosc. 2024. PMID: 39276803
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.
Kuno H, Nishioka N, Yamada T, Kunimatsu Y, Yoshimura A, Hirai S, Futamura S, Masui T, Egami M, Chihara Y, Takayama K. Kuno H, et al. Among authors: nishioka n. Cancers (Basel). 2024 Aug 30;16(17):3037. doi: 10.3390/cancers16173037. Cancers (Basel). 2024. PMID: 39272894 Free PMC article.
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.
Kataoka N, Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Nishioka N, Iwasaku M, Tokuda S, Takayama K. Kataoka N, et al. Among authors: nishioka n. Transl Lung Cancer Res. 2024 Aug 31;13(8):1929-1937. doi: 10.21037/tlcr-24-190. Epub 2024 Aug 20. Transl Lung Cancer Res. 2024. PMID: 39263030 Free PMC article.
WONDER-02: plastic stent vs. lumen-apposing metal stent for endoscopic ultrasound-guided drainage of pancreatic pseudocysts-study protocol for a multicentre randomised non-inferiority trial.
Saito T, Takenaka M, Kuwatani M, Doi S, Ohyama H, Fujisawa T, Masuda A, Iwashita T, Shiomi H, Hayashi N, Iwata K, Maruta A, Mukai T, Matsubara S, Hamada T, Inoue T, Matsumoto K, Hirose S, Fujimori N, Kashiwabara K, Kamada H, Hashimoto S, Shiratori T, Yamada R, Kogure H, Nakahara K, Ogura T, Kitano M, Yasuda I, Isayama H, Nakai Y; WONDERFUL study group in Japan and collaborators. Saito T, et al. Trials. 2024 Aug 24;25(1):559. doi: 10.1186/s13063-024-08373-6. Trials. 2024. PMID: 39182137 Free PMC article.
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Kijima T, Takayama K. Tachibana Y, et al. Among authors: nishioka n. Invest New Drugs. 2024 Aug 21. doi: 10.1007/s10637-024-01467-7. Online ahead of print. Invest New Drugs. 2024. PMID: 39168900
485 results